Literature DB >> 28035538

Effect of Poria cocos hydroethanolic extract on treating adriamycin-induced rat model of nephrotic syndrome.

Jun-Feng Zan1,2, Chan-Juan Shen1, Li-Ping Zhang1, Yan-Wen Liu3,4.   

Abstract

OBJECTIVE: To evaluate the effect of Poria cocos (Schw.) Wolf hydroethanolic extract (PHE) against nephrotic syndrome (NS) in rats and to identify the potential active components from PHE.
METHODS: The high content compounds were isolated and purified by using column chromatography followed by preparative highperformance liquid chromatography (p-HPLC). Forty male Wistar rats with adriamycin (ADR)-induced NS were randomly divided into 5 groups, 8 in each group: model control group, positive control group (with prednisone treatment), PHE low-dose group, PHE middle-dose group and PHE high-dose group. Another 8 rats were recruited as vehicle control group. All rats received the intragastric administration of corresponding drugs or saline for 30 days. During the experimental period, rats' behavior and appearance were observed and recorded daily, and their body weights were recorded weekly. After treatment, 24-h urine samples were collected to evaluate the urine protein and urine creatinine (Ucr); then the rats were sacrificed to collect carotid blood and to determine the levels of serum total protein (TP), albumin (Alb), globulin (Glo), total cholesterol (TC) and cytokine interlukin-4 (IL-4).
RESULTS: Six acidic components were isolated and identified from the PHE section: pachymic acid, 15α-hydroxydehydrotumulosic acid, trametenolic acid, dehydropachymic acid, 3β-hydroxy-lanosta-7,9(11), 24-trien-21-oic-acid and dehydroeburicoic acid. Compared with the model control group, the urine protein content were significantly decreased in the PHE treatment groups and positive control group (P<0.05), especially PHE middle-dose group (P<0.01). The Ucr values and serum levels of TP, Glo, TC and IL-4 in PHE low- and middle-dose groups were also presented obvious recover tendency as compared with the model control group (P<0.05 or P<0.01). However, positive control group and all PHE groups indicated no significant therapeutic effect on raising Alb value, although PHE low- and middle-dose treatment groups showed better outcomes than positive control group (P>0.05).
CONCLUSIONS: PHE showed an encouraging therapeutic effect against ADR-induced NS in a rat model. PHE might be a group of effective substances for the treatment of NS.

Entities:  

Keywords:  Chinese medicine; Poria cocos; hydroethanolic extract; nephrotic syndrome

Mesh:

Substances:

Year:  2016        PMID: 28035538     DOI: 10.1007/s11655-016-2643-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  36 in total

1.  Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors.

Authors:  U Hille; P Soergel; L Makowski; T Dörk-Bousset; P Hillemanns
Journal:  Lymphat Res Biol       Date:  2012-06       Impact factor: 2.589

2.  Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.

Authors:  D S Goumenos; M Ahuja; P Davlouros; A M El Nahas; C B Brown
Journal:  Clin Nephrol       Date:  2006-05       Impact factor: 0.975

Review 3.  Nephrotic syndrome in adults.

Authors:  Richard P Hull; David J A Goldsmith
Journal:  BMJ       Date:  2008-05-24

4.  The nephrotic syndrome.

Authors:  M Haas
Journal:  N Engl J Med       Date:  1998-09-10       Impact factor: 91.245

5.  The nephrotic syndrome.

Authors:  Z Barzilay; G Paret
Journal:  N Engl J Med       Date:  1998-09-10       Impact factor: 91.245

Review 6.  Childhood nephrotic syndrome--current and future therapies.

Authors:  Larry A Greenbaum; Rainer Benndorf; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

Review 7.  Renal toxicity of the nonsteroidal anti-inflammatory drugs.

Authors:  M D Murray; D C Brater
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

Review 8.  Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations.

Authors:  R J Cody
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: cell-cycle arrest and apoptosis induction.

Authors:  Mei Zhang; Lawrence C-M Chiu; Peter C K Cheung; Vincent E C Ooi
Journal:  Oncol Rep       Date:  2006-03       Impact factor: 3.906

10.  Anti-Hyperglycemic Properties of Crude Extract and Triterpenes from Poria cocos.

Authors:  Tzu-Hsuan Li; Chia-Chung Hou; Cicero Lee-Tian Chang; Wen-Chin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-16       Impact factor: 2.629

View more
  4 in total

1.  Exploring protective effect of Glycine tabacina aqueous extract against nephrotic syndrome by network pharmacology and experimental verification.

Authors:  Lihua Tan; Yanbei Tu; Kai Wang; Bing Han; Hongquan Peng; Chengwei He
Journal:  Chin Med       Date:  2020-08-01       Impact factor: 5.455

2.  Metabolome analysis of key genes for synthesis and accumulation of triterpenoids in Wolfiporia cocos.

Authors:  GuiPing Zeng; Zhong Li; Zhi Zhao
Journal:  Sci Rep       Date:  2022-01-28       Impact factor: 4.379

Review 3.  Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms.

Authors:  Yunlai Wang; Ye Feng; Manman Li; Mo Yang; Gaoxiang Shi; Zihua Xuan; Dengke Yin; Fan Xu
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

4.  Analysis of weighted gene co-expression network of triterpenoid-related transcriptome characteristics from different strains of Wolfiporia cocos.

Authors:  Guiping Zeng; Zhong Li; Zhi Zhao
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.